Sanofi Pasteur will stop producing its version of the bladder-cancer drug treatment BCG, sold as TheraCys/ImmuCyst, in mid-2017, the company said in a statement Nov. 18.
Sanofi hasn’t supplied BCG in the U.S. since 2012; the company said it will continue to supply doses to Canada, France and the U.K., where the product is currently available, until the end of 2018.
Despite taking significant steps to try to correct problems at its Toronto manufacturing plant, Sanofi’s efforts “cannot guarantee the long-term continuity and reliable supply of the product,” the company said in a statement. As a result, Sanofi won’t relaunch the product in the U.S. BCG has been in short supply in the U.S. in recent years because of manufacturing-quality lapses.
Judy Packer-Tursman Published Nov. 21, 2016